This is a video synopsis/summary of a Peer Exchange involving Zahra Mahmoudjafari, PharmD, MBA, BCOP, FHOPA; James Davis, PharmD, BCOP; Victoria Nachar, PharmD, BCOP; Shawn Griffin, PharmD, BCOP; and Robert Mancini, PharmD, BCOP, FHOPA.

In this segment, Mahmoudjafari prompts Davis to discuss emerging therapies and research advancements at ASH. Davis highlights 3 therapies: pelabresib, imetelstat, and navitoclax. Pelabresib, a BCL-2 inhibitor, in combination with ruxolitinib, demonstrated promising results in the MANIFEST trial, including spleen volume reduction and symptom score reduction. Importantly, it showed improvement in bone marrow fibrosis, a potential indicator for patient cure. Navitoclax, a BCL-2 and BCL-XL inhibitor, combined with ruxolitinib, showed a significant spleen volume reduction compared to placebo plus ruxolitinib in the TRANSFORM-1 trial. Adverse events were manageable with dose modification. Imetelstat, an intravenous telomerase inhibitor, exhibited a higher rate of 8-week transfusion independence in the phase 3 IMerge trial. The median transfusion independence duration was approximately a year for responders. These therapies represent promising developments, with ongoing research shaping the landscape of myelofibrosis treatment.

This summary was AI-generated and reviewed by Pharmacy Times^® editorial staff.